Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2008

View Archived Issues

Erythropoietin may have antidepressant activity

Iloperidone effective in double-blind schizophrenia trials

Quetiapine treatment assessed in depression, anxiety and alcoholism

Idenix gives update on development of HCV nucleotide prodrugs IDX-184 and IDX-102

Nektar initiates phase II clinical program for PEG-Irinotecan in colorectal cancer

Phase II trial begins for oral PEG-naloxol in opioid-induced bowel dysfunction

Rigel enrolls patients in phase I R-348 trial in immune disorders

Pipex initiates phase II trial of anti-copper Coprexa for Alzheimer's disease

Toyama initiates phase II study for antiinfluenza agent T-705 in Japan

FDA accepts Icagen's IND application for senicapoc for asthma

FDA approves Can-Fite's IND application for phase I study of CF-102 for liver cancer

Pluristem to initiate phase I clinical trials of PLX-PAD for the treatment of limb ischemia

FDA lifts clinical hold on Vion's phase III trial of Cloretazine for acute AML

FDA grants approval to Compellis and Pennington to begin phase I clinical studies of CP-404

FDA grants approval to Chemokine to initiate phase II trial of CTCE-9908 for liver cancer

Emergent BioSolutions reports positive results from phase II clinical study of typhoid vaccine

Vivus initiates DM-230 extension study for patients in the OB-202 study of Qnexa

CTS-21166 reduces plasma amyloid beta in phase I study

Surface Logix's SLx-2101 reduces blood pressure in phase IIa clinical trial

Pharmion and MethylGene initiate phase II clinical trial of MGCD-0103 with Vidaza

BioAlliance Pharma receives marketing authorization for Loramyc in the U.K. and Denmark

Corthera's phase II clinical trial of relaxin in acute heart failure begins

Novel analgesic agents reported in patent literature

New antiinfective agents disclosed in recent patents

Companies claim novel antidiabetic agents in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...